Stay up to date on recent advances in the multidisciplinary approach to cancer.
FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD
Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.
Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
Chemoradiation Prolongs OS, Maintains QOL in Advanced Gallbladder Cancers
Chemoradiotherapy resulted in lower incidence of local progression, prompting an evaluation of resectability in patients with advanced gallbladder cancers.
Fostering the Future of Psychosocial Care With World Psycho-Oncology Day
Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.
Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Large B-Cell Lymphoma
In a multicenter retrospective study authors examined the impact of prior inotuzumab ozogamicin exposure on the outcomes of brexu-cel therapy in adults with R/R B-cell ALL.
Lung Cancer Screening Adherence Decreases Across Subsequent Testing
Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.
